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Abstract
Background. Low-risk prostate cancer patients enrolled in active
surveillance programs commonly undergo biopsies for examination of
cancer progression. Biopsies are conducted as per a fixed and frequent
schedule (e.g., annual biopsies). Since biopsies are burdensome, pa-
tients do not always comply with the schedule, which increases the
risk of delayed detection of cancer progression.
Objective. Our aim is to better balance the number of biop-
sies (burden) and the delay in detection of cancer progression (less is
beneficial), by personalizing the decision of conducting biopsies.
Data Sources. We use patient data of the world’s largest ac-
tive surveillance program (PRIAS). It enrolled 5270 patients, had 866
cancer progressions, and an average of nine prostate-specific antigen
(PSA) and five digital rectal examination (DRE) measurements per
patient.
Methods. Using joint models for time-to-event and longitudi-
nal data, we model the historical DRE and PSA measurements, and
biopsy results of a patient at each follow-up visit. This results in a
visit and patient-specific cumulative risk of cancer progression. If this
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risk is above a certain threshold, we schedule a biopsy. We compare
this personalized approach with the currently practiced biopsy sched-
ules via an extensive and realistic simulation study, based on a replica
of the patients from the PRIAS program.
Results. The personalized approach saved a median of six biop-
sies (median: 4, IQR: 2–5), compared to the annual schedule (me-
dian: 10, IQR: 3–10). However, the delay in detection of progression
(years) is similar for the personalized (median: 0.7, IQR: 0.3–1.0) and
the annual schedule (median: 0.5, IQR: 0.3–0.8).
Conclusions. We conclude that personalized schedules provide
substantially better balance in the number of biopsies per detected
progression for men with low-risk prostate cancer.
1 Introduction
Prostate cancer is the second most frequently diagnosed cancer in men world-
wide (Torre et al., 2015). In prostate cancer screening programs, many of the
diagnosed tumors are clinically insignificant (over-diagnosed) (Etzioni et al.,
2002). To avoid further over-treatment, patients diagnosed with low-grade
prostate cancer are commonly advised to join active surveillance (AS) pro-
grams. In AS, invasive treatments such as surgery are delayed until cancer
progresses. Cancer progression is routinely monitored via serum prostate-
specific antigen (PSA) measurements, a protein biomarker; digital rectal ex-
amination (DRE) measurements, a measure of the size and location of the
tumor; and biopsies.
While larger values for PSA and/or DRE, may indicate cancer progres-
sion, biopsies are the most reliable cancer progression examination technique
used in AS. When a patient’s biopsy Gleason score becomes larger than 6
(positive biopsy, cancer progression detected), AS is stopped and the patient
is advised treatment (Bokhorst et al., 2015). However, biopsies are invasive,
painful, and prone to medical complications (Ehdaie et al., 2014; Fujita et
al., 2009). Hence, they are conducted intermittently until a positive biopsy.
Consequently, at the time of a positive biopsy, cancer progression may be
observed with a delay of unknown duration. This delay is defined as the
difference between the time of the positive biopsy and the unobserved true
time of cancer progression. Thus, the decision to conduct biopsies requires
a compromise between the burden of biopsy and the potential delay in the
detection of cancer progression.
In AS, a delay in the detection of cancer progression around 12 to 14
months is assumed to be unlikely to substantially increase the risk of adverse
downstream outcomes (Carvalho, Heijnsdijk, and Koning, 2017; Inoue et al.,
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2018). However, for biopsies, there is little consensus on the time gap be-
tween them (Bruinsma et al., 2016; Loeb et al., 2014; Nieboer et al., 2018).
Many AS programs focus on minimizing the delay in the detection of cancer
progression, by scheduling biopsies annually for all patients. A drawback of
annual biopsies, and other currently practiced fixed/heuristic schedules (Bru-
insma et al., 2016; Loeb et al., 2014; Nieboer et al., 2018), is that they ignore
the large variation in the time of cancer progression of AS patients. While
they may work well for patients who progress early (fast progressing) in AS,
but for a large proportion of patients who do not progress, or progress late
(slow progressing) in AS, many unnecessary burdensome biopsies are sched-
uled. To mediate the burden between the fast and slow progressing patients,
the world’s largest AS program, Prostate Cancer Research International Ac-
tive Surveillance (Bokhorst et al., 2016) (PRIAS), schedules annual biopsies
only for patients with a low PSA doubling time (Bokhorst et al., 2015). For
everyone else, PRIAS schedules biopsies at following fixed follow-up times:
year one, four, seven, and ten, and every five years thereafter. Despite this
effort in PRIAS, patients may get scheduled for four to ten biopsies over
a period of ten years. Therefore, compliance for biopsies is low in PRIAS
(Bokhorst et al., 2015). This can lead to a delay in the detection of cancer
progression, and reduce the effectiveness of AS.
We aim to better balance the number of biopsies (more are burdensome),
and the delay in the detection of cancer progression (less is beneficial), than
currently practiced schedules. We intend to achieve this by personalizing
the decision to conduct biopsies (see Figure 1). These decisions are made at
a patient’s pre-scheduled follow-up visits for DRE and PSA measurements.
To develop the personalized decision making methodology, we utilize the
data of the patients enrolled in the PRIAS study. We model this data and
develop the personalized approach using joint models for time-to-event and
longitudinal data (Rizopoulos, 2012; Tsiatis and Davidian, 2004). In order
to compare the personalized approach with current schedules, we conduct an
extensive simulation study based on a replica of the patients from the PRIAS
program.
2 Methods
2.1 Study Population
To develop our methodology we use the data of prostate cancer patients
from the world’s largest AS study called PRIAS (Bokhorst et al., 2016) (see
Table 1). More than 100 medical centers from 17 countries worldwide con-
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Figure 1: The personalized decision making problem: Available data
of a patient j, who had his latest negative biopsy at t = 2.6 years. The
shaded region shows the time period in which the patient is at risk of cancer
progression. His current pre-scheduled follow-up visit for measurement of
DRE and PSA is at s = 4 years. Using his entire history of DRE Ydj(s)
and PSA Ypj(s) measurements up to the current visit s, and the time of the
latest biopsy t, we intend to make a decision on scheduling a biopsy at the
current visit.
tribute to the collection of data, utilizing a common study protocol and a
web-based tool, both available at www.prias-project.org. We use data
collected over a period of ten years, between December 2006 (beginning of
PRIAS study) and December 2016. The primary event of interest is cancer
progression detected upon a positive biopsy. The time of cancer progression
is interval censored because biopsies are scheduled periodically. Biopsies are
scheduled as per the PRIAS protocol (see Introduction). There are three
types of competing events, namely death, removal of patients from AS on
the basis of their observed DRE and PSA measurements, and loss to follow-
up. We assume these three types of events to be censored observations (see
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Table 1: Summary statistics for the PRIAS dataset. The primary event
of interest is cancer progression. A DRE measurement equal to T1cSchro¨der
et al., 1992 indicates a clinically inapparent tumor which is not palpable
or visible by imaging, while tumors with DRE > T1c are palpable. The
abbreviation IQR means interquartile range.
Data Value
Total patients 5270
Cancer progression (primary event) 866
Loss to follow-up (anxiety or unknown) 685
Removal on the basis of PSA and DRE 464
Death (unrelated to prostate cancer) 61
Death (related to prostate cancer) 2
Median Age (years) 70 (IQR: 65–75)
Total PSA measurements 46015
Median number of PSA per patient 7 (IQR: 7–12)
Median PSA value (ng/mL) 5.6 (IQR: 4.0–7.5)
Total DRE measurements 25606
Median number of DRE per patient 4 (IQR: 3–7)
DRE = T1c (%) 23538/25606 (92%)
Appendix A.5 for details). However, our model allows removal of patients
to depend on observed longitudinal data and baseline covariates of the pa-
tient. Under the aforementioned assumption of censoring, Figure 2 shows
the cumulative risk of cancer progression over the study follow-up period.
For all patients, PSA measurements (ng/mL) are scheduled every 3 months
for the first 2 years and every 6 months thereafter. The DRE measurements
are scheduled every 6 months. We use the DRE measurements as DRE = T1c
versus DRE > T1c. A DRE measurement equal to T1c (Schro¨der et al.,
1992) indicates a clinically inapparent tumor which is not palpable or visible
by imaging, while tumors with DRE > T1c are palpable.
Data Accessibility: The PRIAS database is not openly accessible.
However, access to the database can be requested on the basis of a study
proposal approved by the PRIAS steering committee. The website of the
PRIAS program is www.prias-project.org.
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Figure 2: Estimated cumulative risk of cancer progression in AS for
patients in the Prostate Cancer Research International Active Surveillance
(PRIAS) dataset. Nearly 50% patients (slow progressing) do not progress
in the ten year follow-up period. Cumulative risk is estimated using non-
parametric maximum likelihood estimation (Turnbull, 1976), to account for
interval censored cancer progression times observed in the PRIAS dataset.
Censoring includes death, removal from AS on the basis of observed longitu-
dinal data, and patient dropout.
2.2 A Bivariate Joint Model for the Longitudinal PSA,
and DRE Measurements, and Time of Cancer Pro-
gression
Let T ∗i denote the true cancer progression time of the i-th patient included
in PRIAS. Since biopsies are conducted periodically, T ∗i is observed with in-
terval censoring li < T
∗
i ≤ ri. When progression is observed for the patient
at his latest biopsy time ri, then li denotes the time of the second latest
biopsy. Otherwise, li denotes the time of the latest biopsy and ri =∞.
Let ydi and ypi denote his observed DRE and PSA longitudinal measure-
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ments, respectively. The observed data of all n patients is denoted by
Dn = {li, ri,ydi,ypi; i = 1, . . . , n}.
In our joint model, the patient-specific DRE and PSA measurements over
time are modeled using a bivariate generalized linear mixed effects sub-model.
The sub-model for DRE is given by (see Panel A, Figure 3):
logit
[
Pr{ydi(t) > T1c}
]
= β0d + b0di + (β1d + b1di)t
+ β2d(Agei − 70)
+ β3d(Agei − 70)
2 (1)
where, t denotes the follow-up visit time, and Agei is the age of the i-th
patient at the time of inclusion in AS. We have centered the Age variable
around the median age of 70 years for better convergence during parameter
estimation. However, this does not change the interpretation of the param-
eters corresponding to the Age variable. The fixed effect parameters are
denoted by {β0d, . . . , β3d}, and {b0di, b1di} are the patient specific random ef-
fects. With this definition, we assume that the patient-specific log odds of
obtaining a DRE measurement larger than T1c remain linear over time.
The mixed effects sub-model for PSA is given by (see Panel B, Figure 3):
log2
{
ypi(t) + 1
}
= mpi(t) + εpi(t),
mpi(t) = β0p + b0pi +
4∑
k=1
(βkp + bkpi)Bk(t,K)
+ β5p(Agei − 70) + β6p(Agei − 70)
2, (2)
where, mpi(t) denotes the underlying measurement error free value of log2(PSA+
1) transformed (Lin et al., 2000; Pearson et al., 1994) measurements at time
t. We model it non-linearly over time using B-splines (De Boor, 1978).
To this end, our B-spline basis function Bk(t,K) has 3 internal knots at
K = {0.1, 0.7, 4} years, and boundary knots at 0 and 5.42 years (95-th per-
centile of the observed follow-up times). This specification allows fitting the
log2(PSA + 1) levels in a piecewise manner for each patient separately. The
internal and boundary knots specify the different time periods (analogously
pieces) of this piecewise nonlinear curve. The fixed effect parameters are de-
noted by {β0p, . . . , β6p}, and {b0pi, . . . , b4pi} are the patient specific random
effects. The error εpi(t) is assumed to be t-distributed with three degrees of
freedom (see Appendix B.1) and scale σ, and is independent of the random
effects.
To account for the correlation between the DRE and PSA measurements
of a patient, we link their corresponding random effects. More specifically, the
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complete vector of random effects bi = (b0di, b1di, b0pi, . . . , b4pi)
T is assumed
to follow a multivariate normal distribution with mean zero and variance-
covariance matrix D.
To model the impact of DRE and PSA measurements on the risk of cancer
progression, our joint model uses a relative risk sub-model. More specifically,
the hazard of cancer progression hi(t) at a time t is given by (see Panel D,
Figure 3):
hi(t) = h0(t) exp
(
γ1(Agei − 70) + γ2(Agei − 70)
2
+ α1dlogit
[
Pr{ydi(t) > T1c}
]
+ α1pmpi(t) + α2p
∂mpi(t)
∂t
)
, (3)
where, γ1, γ2 are the parameters for the effect of age. The parameter α1d
models the impact of log odds of obtaining a DRE > T1c on the hazard of
cancer progression. The impact of PSA on the hazard of cancer progression
is modeled in two ways: a) the impact of the error free underlying PSA value
mpi(t) (see Panel B, Figure 3), and b) the impact of the underlying PSA
velocity ∂mpi(t)/∂t (see Panel C, Figure 3). The corresponding parameters
are α1p and α2p, respectively. Lastly, h0(t) is the baseline hazard at time t,
and is modeled flexibly using P-splines (Eilers and Marx, 1996). The detailed
specification of the baseline hazard h0(t), and the joint parameter estimation
of the two sub-models using the Bayesian approach (R package JMbayes,
see Rizopoulos, 2016) are presented in Appendix A of the supplementary
material.
2.3 Personalized Decisions for Biopsy
Let us assume that a decision of conducting a biopsy is to be made for a
new patient j shown in Figure 1, at his current follow-up visit time s. Let
t ≤ s be the time of his latest negative biopsy. Let Ydj(s) and Ypj(s) denote
his observed DRE and PSA measurements up to the current visit, respec-
tively. From the observed measurements we want to extract the underlying
measurement error free trend of log2(PSA + 1) values and velocity, and the
log odds of obtaining DRE > T1c. We intend to combine them to inform us
when the cancer progression is to be expected (see Figure 4), and to further
guide the decision making on whether to conduct a biopsy at the current
follow-up visit. The combined information is given by the following poste-
rior predictive distribution g(T ∗j ) of his time of cancer progression T
∗
j > t
(see Appendix A.4 for details):
g(T ∗j ) = p
{
T ∗j | T
∗
j > t,Ydj(s),Ypj(s),Dn
}
. (4)
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The distribution g(T ∗j ) is not only patient-specific, but also updates as extra
information is recorded at future follow-up visits.
A key ingredient in the decision of conducting a biopsy for patient j at the
current follow-up visit time s is the personalized cumulative risk of observing
a cancer progression at time s (illustrated in Figure 4). This risk can be
derived from the posterior predictive distribution g(T ∗j ) (Rizopoulos, 2011),
and for s ≥ t it is given by:
Rj(s | t) = Pr
{
T ∗j ≤ s | T
∗
j > t,Ydj(s),Ypj(s),Dn
}
. (5)
A simple and straightforward approach to decide upon conducting a biopsy
for patient j at the current follow-up visit would be to do so if his personalized
cumulative risk of cancer progression at the visit is higher than a certain
threshold 0 ≤ κ ≤ 1. For example, as shown in Panel B of Figure 4, biopsy
at a visit may be scheduled if the personalized cumulative risk is higher
than 10% (example risk threshold). This decision making process is iterated
over the follow-up period, incorporating on each subsequent visit the newly
observed data, until a positive biopsy is observed. Subsequently, an entire
personalized schedule of biopsies for each patient can be obtained.
The choice of the risk threshold dictates the schedule of biopsies and has
to be made on each subsequent follow-up visit of a patient. In this regard, a
straightforward approach is choosing a fixed risk threshold, such as 5% or 10%
risk, at all follow-up visits. Fixed risk thresholds may be chosen by patients
and/or doctors according to how they weigh the relative harms of doing an
unnecessary biopsy versus a missed cancer progression (e.g., 10% threshold
means a 1:9 ratio) if the biopsy is not conducted (Vickers and Elkin, 2006).
An alternative approach is that at each follow-up visit a unique threshold is
chosen on the basis of its classification accuracy. More specifically, given the
time of latest biopsy t of patient j, and his current visit time s we find a
visit-specific biopsy threshold κ, which gives the highest cancer progression
detection rate (true positive rate, or TPR) for the period (t, s]. However,
we also intend to balance for unnecessary biopsies (high false positive rate),
or a low number of correct detections (high false negative rate) when the
false positive rate is minimized. An approach to mitigating these issues is
to maximize the TPR and positive predictive value (PPV) simultaneously.
To this end, we utilize the F1 score, which is a composite of both TPR and
PPV (estimated as in Rizopoulos et al., 2017 Rizopoulos, Molenberghs, and
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Lesaffre, 2017), and is defined as:
F1(t, s, κ) = 2
TPR(t, s, κ) PPV(t, s, κ)
TPR(t, s, κ) + PPV(t, s, κ)
,
TPR(t, s, κ) = Pr
{
Rj(s | t) > κ | t < T
∗
j ≤ s
}
,
PPV(t, s, κ) = Pr
{
t < T ∗j ≤ s | Rj(s | t) > κ
}
, (6)
where, TPR(t, s, κ) and PPV(t, s, κ) are the time dependent true positive rate
and positive predictive value, respectively. These values are unique for each
combination of the time period (t, s] and the risk threshold κ that is used to
discriminate between the patients whose cancer progresses in this time period
versus the patients whose cancer does not progress. The same holds true for
the resulting F1 score denoted by F1(t, s, κ). The F1 score ranges between 0
and 1, where a value equal to 1 indicates perfect TPR and PPV. Thus the
highest F1 score is desired in each time period (t, s]. This can be achieved
by choosing a risk threshold κ which maximizes F1(t, s, κ). That is, during a
patient’s visit at time s, given that his latest biopsy was at time t, the visit-
specific risk threshold to decide a biopsy is given by κ = argmaxκ F1(t, s, κ).
The criteria on which we evaluate the personalized schedules based on fixed
and visit-specific risk thresholds is the total number of biopsies scheduled,
and the delay in detection of cancer progression (details in Results).
2.4 Simulation Study
Although the personalized decision making approach is motivated by the
PRIAS study, it is not possible to evaluate it directly on the PRIAS dataset.
This is because the patients in PRIAS have already had their biopsies as
per the PRIAS protocol. In addition, the true time of cancer progression is
interval or right censored for all patients, making it impossible to correctly
estimate the delay in detection of cancer progression due to a particular
schedule. To this end, we conduct an extensive simulation study to find the
utility of personalized, PRIAS, and fixed/heuristic schedules. For a realistic
comparison, we simulate patient data from the joint model fitted to the
PRIAS dataset. The simulated population has the same ten year follow-
up period as the PRIAS study. In addition, the estimated relations between
DRE and PSA measurements, and the risk of cancer progression are retained
in the simulated population.
From this population, we first sample 500 datasets, each representing a
hypothetical AS program with 1000 patients in it. We generate a true cancer
progression time for each of the 500× 1000 patients and then sample a set
of DRE and PSA measurements at the same follow-up visit times as given
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in PRIAS protocol. We then split each dataset into training (750 patients)
and test (250 patients) parts, and generate a random and noninformative
censoring time for the training patients. We next fit a joint model of the
specification given in Equations (1), (2), and (3) to each of the 500 train-
ing datasets and obtain MCMC samples from the 500 sets of the posterior
distribution of the parameters.
In each of the 500 hypothetical AS programs, we utilize the correspond-
ing fitted joint models to develop cancer progression risk profiles for each of
the 500× 250 test patients. We make the decision of biopsies for patients
at their pre-scheduled follow-up visits for DRE and PSA measurements (see
Study Population), on the basis of their estimated personalized cumulative
risk of cancer progression. These decisions are made iteratively until a posi-
tive biopsy is observed. A recommended gap of one year between consecutive
biopsies (Bokhorst et al., 2015) is also maintained. Subsequently, for each
patient, an entire personalized schedule of biopsies is obtained.
We evaluate and compare both personalized and currently practiced sched-
ules of biopsies in this simulation study. Comparison of the schedules is based
on the number of biopsies scheduled and the corresponding delay in the de-
tection of cancer progression. We evaluate the following currently practiced
fixed/heuristic schedules: biopsy annually, biopsy every one and a half years,
biopsy every two years and biopsy every three years. We also evaluate the
biopsy schedule of the PRIAS program (see Introduction). For the personal-
ized biopsy schedules, we evaluate schedules based on three fixed risk thresh-
olds: 5%, 10%, and 15%, corresponding to a missed cancer progression being
19, 9, and 5.5 times more harmful than an unnecessary biopsy (Vickers and
Elkin, 2006), respectively. We also implement a personalized schedule where
for each patient, visit-specific risk thresholds are chosen using F1 score.
3 Results
From the joint model fitted to the PRIAS dataset, we found that both
log2{PSA + 1} velocity, and log odds of having DRE > T1c were signifi-
cantly associated with the hazard of cancer progression. For any patient,
an increase in log2{PSA + 1} velocity from -0.03 to 0.16 (first and third
quartiles of the fitted velocities, respectively) corresponds to a 1.94 fold in-
crease in the hazard of cancer progression. Whereas, an increase in odds
of DRE > T1c from -6.650 to -4.356 (first and third quartiles of the fitted
log odds, respectively) corresponds to a 1.40 fold increase in the hazard of
cancer progression. Detailed results pertaining to the fitted joint model are
presented in Appendix B.
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3.1 Comparison of Various Approaches for Biopsies
From the simulation study, we obtain the number of biopsies and the de-
lay in detection of cancer progression for each of the 500× 250 test patients
using different schedules. Figure 5 shows that the personalized and PRIAS
approaches fall in the region of better balance between the median number
of biopsies and the median delay than fixed/heuristic schedules. We next
evaluate these schedules on the basis of both median and interquartile range
(IQR) of the number of biopsies and delay (see Figure 6). For brevity, only
the most widely used annual and PRIAS schedules, the proposed personal-
ized approach with fixed risk thresholds of 5% and 10%, and visit-specific
threshold chosen using F1 score are discussed next (see Appendix C for re-
maining).
Since patients have varying cancer progression speeds, the impact of each
schedule also varies with it. In order to highlight these differences, we divide
results for three types of patients, as per their time of cancer progression.
They are fast, intermediate, and slow progressing patients. Although such
a division may be imperfect and can only be done retrospectively in a sim-
ulation setting, we show results for these three groups for the purpose of
illustration. Roughly 50% of the patients did not obtain cancer progression
in the ten year follow-up period of the simulation study. We assume these
patients to be slow progressing patients. We assume fast progressing patients
are the ones with an initially misdiagnosed state of cancer (Cooperberg et al.,
2011) or high-risk patients who choose AS instead of immediate treatment
upon diagnosis. These are roughly 30% of the population, having a cancer
progression time less than 3.5 years. We label the remaining 20% patients
as intermediate progressing patients.
For fast progressing patients (Panel A, Figure 6), we note that the person-
alized schedules with a fixed 10% risk threshold and visit-specific threshold
chosen using F1 score, reduce one biopsy for 50% of the patients, compared to
PRIAS and annual schedule. Despite this, the delay (years) is similar for the
personalized schedule with fixed 10% risk threshold (median: 0.7, IQR: 0.3–
1.0), and the commonly used annual (median: 0.6, IQR: 0.3–0.9) and PRIAS
(median: 0.7, IQR: 0.3–1.0) schedules.
For intermediate progressing patients (Panel A, Figure 6), we note that
the delay (years) due to personalized schedule with fixed 5% risk threshold
(median: 0.6, IQR: 0.3–0.9) is comparable to that of annual schedule (median
0.5, IQR: 0.2–0.7). However, it schedules fewer biopsies (median: 6, IQR: 5–
7) than the annual schedule (median: 7, IQR: 5–8). The delay (years) for
PRIAS (median: 0.7, IQR: 0.3–1.3) and personalized schedule with fixed 10%
risk (median: 0.7, IQR: 0.4–1.3) are similar, but the personalized approach
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schedules one less biopsy for 50% of the patients. Although the approach with
visit-specific risk threshold chosen using F1 score schedules fewer biopsies
than the 10% fixed risk approach, it also has a higher delay.
The patients who are at the most advantage with the personalized sched-
ules are the slow progressing patients. These are a total of 50% patients who
did not progress during the entire study. Hence, the delay is not available
for these patients (Panel C of Figure 6). For all of these patients, annual
schedule leads to 10 (unnecessary) biopsies. The schedule of the PRIAS
program schedules a median of six biopsies (IQR: 4–8). In comparison,
the biopsies scheduled by the personalized schedules using fixed 10% risk
threshold (median: 4, IQR: 4–6) and visit-specific risk chosen using F1 score
(median: 2, IQR: 2–4), are much fewer.
Overall, we observed that the personalized schedule which uses a 10%
risk threshold at all follow-up visits is dominant over the PRIAS schedule,
biennial schedule of biopsies, and biopsies every one and a half years (see Ap-
pendix C for the latter two schedules). This personalized schedule not only
schedules fewer biopsies than the aforementioned currently practiced sched-
ules, but the delay in detection of cancer progression is also either equal or
less. The personalized schedule which uses risk threshold chosen on the basis
of classification accuracy (F1 score) is dominant over the triennial schedule
(see Appendix C) of biopsies. The personalized schedule which uses a 5%
risk threshold schedules fewer biopsies than the annual schedule, while the
delay is only trivially more than the annual schedule.
4 Discussion
We proposed a methodology which better balances the number of biopsies,
and the delay in detection of cancer progression than the currently prac-
ticed biopsy schedules, for low-risk prostate cancer patients enrolled in active
surveillance (AS) programs. The proposed methodology combines a patient’s
observed DRE and PSA measurements, and the time of the latest biopsy,
into a personalized cancer progression risk function. If the cumulative risk
of cancer progression at a follow-up visit is above a certain threshold, then a
biopsy is scheduled. We conducted an extensive simulation study, based on
a replica of the patients from the PRIAS program, to compare this person-
alized approach for biopsies with the currently practiced biopsy schedules.
We found personalized schedules to be dominant over many of the current
biopsy schedules (see Results).
The main reason for the better performance of personalized schedules
is that they account for the variation in cancer progression rate between
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patients, and also over time within the same patient. In contrast, the exist-
ing fixed/heuristic schedules ignore that roughly 50% of the patients never
progress in the first ten years of follow-up (slow progressing patients) and do
not require biopsies. The fast progressing patients require early detection.
However, existing methods of identifying these patients, such as the use of
PSA doubling time in PRIAS, inappropriately assume that PSA evolves lin-
early over time. Thus, they may not correctly identify such patients. The
personalized approach, however, models the PSA profiles non-linearly. Fur-
thermore, it appends information from PSA with information from DRE and
previous biopsy results and combines them into a single a cancer progression
risk function. The risk function is a finer quantitative measure than individ-
ual data measurements observed for the patients. In comparison to decision
making with flowcharts, the risk as a single measure of a patient’s underlying
state of cancer may facilitate shared decision making for biopsies.
Existing work on reducing the burden of biopsies in AS primarily advo-
cates less frequent heuristic schedules of biopsies (Inoue et al., 2018) (e.g.,
biopsies biennially instead of annually). To our knowledge, risk-based biopsy
schedules have barely been explored yet in AS (Bruinsma et al., 2016; Nieboer
et al., 2018). The part of our results pertaining to the fixed/heuristic sched-
ules is comparable with corresponding results obtained in existing work (In-
oue et al., 2018), even though the AS cohorts are not the same. Thus,
we anticipate similar validity for the results pertaining to the personalized
schedules.
A limitation of the personalized approach is that the choice of risk thresh-
old is not straightforward, as different thresholds lead to different combina-
tions of the number of biopsies and the delay in detection of cancer progres-
sion. An approach is to choose a risk threshold which leads to personalized
schedule dominant (e.g., 10% risk) over the currently practiced schedules, for
a given delay. Since personalized biopsy schedules are less burdensome, they
may lead to better compliance. A second limitation is that the results that
we presented are valid only in a 10 year follow-up period, whereas prostate
cancer is a slow progressing disease. Thus more detailed results, especially
for slow progressing patients cannot be estimated. However, very few AS co-
horts have a longer follow-period than PRIAS (Bruinsma et al., 2016). In a
screening setting often the ethno-racial background of the patient, as well as
the history of cancer in first degree relatives are checked. Our model does not
take into account either. The reason is that the history of cancer in relatives
been found to be predictive of cancer progression only in African-American
patients (Goh et al., 2013; Telang et al., 2017). This is also evident by the
fact that PRIAS and many other surveillance programs do not utilize this
information in their biopsy protocols (Bokhorst et al., 2016; Nieboer et al.,
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2018). In addition, patients who have a higher risk of an aggressive form of
cancer are usually not recommended active surveillance. Hence the proposed
model is relevant only for low-risk prostate cancer patients eligible for active
surveillance. An exception is the active surveillance patients who are old
and/or have comorbid illnesses. Currently, such patients may be removed
from active surveillance and are instead offered the less intensive watchful
waiting (Bokhorst et al., 2016) option. It is also possible to model watchful
waiting as a competing risk in our model. However, this falls outside the
scope of the current work because cancer progression as detected via biopsy
is the standard trigger for treatment advice. Lastly, our results are not valid
when the patient data is missing not at random (MNAR).
There are multiple ways to extend the personalized decision making ap-
proach. For example, biopsy Gleason grading is susceptible to inter-observer
variation (Coley et al., 2017). Thus accounting for it in our model will be
interesting to investigate further. To improve the decision making method-
ology, future consequences of a biopsy can be accounted for in the model
by combining Markov decision processes with joint models for time-to-event
and longitudinal data. There is also a potential for including diagnostic in-
formation from magnetic resonance imaging (MRI), such as the volume of
the prostate tumor as a longitudinal measurement in our model. The re-
sulting predictions can be used to the decide the time of next MRI as well
as to make a decision of biopsy. The same holds true for the quality of life
measures as well. However, given the scarceness of both MRI and quality of
life measurements in the dataset, including them in the current model may
not be feasible. We intend to further validate our results in a multi-center
AS cohort, and subsequently develop a web application to assist in making
shared decisions for biopsies.
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Figure 3: Illustration of the joint model fitted to the PRIAS dataset.
Panel A: shows the observed DRE measurements and the fitted probability
of obtaining DRE > T1c (Equation 1) for i-th patient. Panel B: shows the
observed and fitted log2(PSA + 1) measurements (Equation 2). Panel C:
shows the estimated log2(PSA + 1) velocity (velocity cannot be observed
directly) over time. The hazard function (Equation 3) shown in Panel D,
depends on the fitted log odds of having a DRE > T1c, and the fitted
log2(PSA + 1) value and velocity.
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Figure 4: Illustration of personalized decision of biopsy for patient j
at two different follow-up visits. Biopsy is recommended if the personalized
cumulative risk of cancer progression estimated from the joint model fitted
to the observed data of the patient, is higher than the example risk threshold
for biopsy (κ = 10%). Panel A: biopsy is not recommended for the patient
j at the follow-up visit time s = 4 years, because his estimated personal-
ized cumulative risk of cancer progression (7.8%) is less than the threshold.
Panel B: biopsy is recommended for the patient j at the follow-up visit time
s = 5.3 years, because his estimated personalized cumulative risk of cancer
progression (13.5%) is more than the threshold.
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Figure 5: Burden-biopsy frontier: Median number of biopsies (X-
axis), and median delay in detection of cancer progression (in years, Y-
axis), estimated from the simulation study. Results for currently practiced
fixed/heuristic biopsy schedules are shown by red squares, for PRIAS sched-
ule by a blue rhombus, and for personalized schedules by green triangles.
Types of personalized schedules: Risk: 15%, Risk: 10%, and Risk: 5%
approaches, schedule a biopsy if the cumulative risk of cancer progression at
a visit is more than 15%, 10%, and 5%, respectively. Risk: F1 works sim-
ilar as previous, except that for each patient, a visit-specific risk threshold
is chosen by maximizing F1 score (see Methods). The green shaded region
depicts the region of better balance in the median number of biopsies and
median delay than the currently practiced fixed/heuristic schedules.
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Figure 6: Boxplot showing variation in the number of biopsies, and the delay
in detection of cancer progression, in years (time of positive biopsy - true
time of cancer progression) for various biopsy schedules. Biopsies are con-
ducted until cancer progression is detected. Panel A: results for simulated
patients who had a faster speed of cancer progression, with progression times
between 0 and 3.5 years. Panel B: results for simulated patients who had
an intermediate speed of cancer progression, with progression times between
3.5 and 10 years. Panel C: results for simulated patients who did not have
cancer progression in the ten years of follow-up. Types of personalized
schedules: Risk: 10% and Risk: 5% approaches, schedule a biopsy if the
cumulative risk of cancer progression at a visit is more than 10% and 5%,
respectively. Risk: F1 works similar as previous, except that a visit-specific
risk threshold is chosen by maximizing F1 score (see Methods). Annual cor-
responds to a schedule of yearly biopsies and PRIAS corresponds to biopsies
as per PRIAS protocol (see Introduction).
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